BRIEF

on SANOFI-AVENTIS (EPA:SAN)

Sanofi's VaxRabeo Rabies Vaccine Gains EU Approval for All Ages

Stock price chart of SANOFI-AVENTIS (EPA:SAN) showing fluctuations.

On November 19, 2026, Sanofi announced the European Commission's approval of VaxRabeo, a next-generation rabies vaccine for all age groups. This marks VaxRabeo's first marketing authorization, following a positive opinion by the European Medicines Agency. The vaccine is designed for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) and is developed using advanced Vero-cell technology enhancing its safety and shelf life.

Rabies, a zoonotic disease causing over 59,000 deaths annually, is preventable by vaccination. VaxRabeo demonstrated effective antibody responses comparable to existing vaccines, in PrEP and PEP scenarios with similar immunogenicity and safety profiles.

Sanofi emphasizes this development as a pivotal milestone in their ongoing commitment to combat rabies. With VaxRabeo's approval, the company aims to enhance global healthcare systems with modern preventive tools against rabies.

R. E.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all SANOFI-AVENTIS news